Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review.

[1]  L. Pusztai,et al.  Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Spanheimer,et al.  The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment , 2022, NPJ breast cancer.

[3]  G. Curigliano,et al.  Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? , 2022, Breast Cancer Research and Treatment.

[4]  K. Gogineni,et al.  Individualizing Adjuvant Therapy in Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Node-Positive Breast Cancer. , 2022, JCO oncology practice.

[5]  G. Hortobagyi,et al.  21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. , 2021, The New England journal of medicine.

[6]  S. Barni,et al.  Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study , 2021, Breast Cancer Research and Treatment.

[7]  H. Putter,et al.  Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study. , 2021, The Lancet. Healthy longevity.

[8]  S. Plumb,et al.  Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study , 2021, The Lancet.

[9]  E. Brain.  PORTRET, a more inclusive portrait of the older population with breast cancer. , 2021, The Lancet. Healthy longevity.

[10]  M. Fakih,et al.  Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial. , 2021, JAMA oncology.

[11]  L. Biganzoli,et al.  Systemic therapy for early breast cancer in older adults: current status and prospects , 2021, Current opinion in oncology.

[12]  A. Brennan,et al.  Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer , 2020, European journal of cancer.

[13]  H. Wildiers,et al.  Anticancer drugs are not well tolerated in all older patients with cancer. , 2020, The Lancet. Healthy longevity.

[14]  G. Babiera,et al.  Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. , 2020, JAMA oncology.

[15]  L. Biganzoli,et al.  The Conundrum of the Association of Chemotherapy With Survival Outcomes Among Elderly Patients With Curable Luminal Breast Cancer. , 2020, JAMA oncology.

[16]  N. Camp,et al.  21-gene recurrence score testing utilization among older women from different races: A population-based study. , 2020, Journal of geriatric oncology.

[17]  M. King,et al.  Integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. , 2020 .

[18]  G. Abel,et al.  Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Shak,et al.  Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy , 2019, npj Breast Cancer.

[20]  Lin Lin,et al.  Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer. , 2019, Journal of geriatric oncology.

[21]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[22]  H. Cohen,et al.  Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Bingshu E. Chen,et al.  Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials , 2019, The Lancet.

[24]  E. Jensen,et al.  21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer. , 2019, Journal of geriatric oncology.

[25]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[26]  H. Cohen,et al.  Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Neven,et al.  The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancer. , 2017, Journal of geriatric oncology.

[28]  N. Howlader,et al.  Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR+) breast cancer (BC) , 2016 .

[29]  L. V. van't Veer,et al.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.

[30]  P. Neven,et al.  The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters , 2016, Oncotarget.

[31]  S. Swain,et al.  Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age , 2015, Advances in Therapy.

[32]  C. Denkert,et al.  A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52) , 2015, Cancer.

[33]  S. Barni,et al.  Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  C. Perou,et al.  Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. , 2014, The oncologist.

[35]  C. Bombardier,et al.  Assessing Bias in Studies of Prognostic Factors , 2013, Annals of Internal Medicine.

[36]  F. André,et al.  ASTER 70s: Benefit of adjuvant chemotherapy for estrogen receptor-positive HER2-negative breast cancer in women over 70 according to genomic grade—A French GERICO/UCBG UNICANCER multicenter phase III trial. , 2012 .

[37]  T. Reimer,et al.  The 70-Gene Signature as Prognostic Factor for Elderly Women with Hormone Receptor-Positive, HER2-Negative Breast Cancer , 2012, Breast Care.

[38]  E. Blot,et al.  Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial. , 2011, Critical reviews in oncology/hematology.

[39]  H. Cohen,et al.  Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  H. Cohen,et al.  Adjuvant chemotherapy in older women with early-stage breast cancer. , 2009, The New England journal of medicine.

[41]  F. Holmes,et al.  Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  G. D'aiuto,et al.  Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. , 2008, Critical reviews in oncology/hematology.

[43]  Christopher Poole,et al.  Polychemotherapy for Early Breast Cancer: Results From the International Adjuvant Breast Cancer Chemotherapy Randomized Trial , 2007 .

[44]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[45]  W. Satariano,et al.  The Effect of Comorbidity on 3-Year Survival of Women with Primary Breast Cancer , 1994, Annals of Internal Medicine.

[46]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.